- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
8 Pharma Firms including Mylan, Aurobindo Pharma to pay Rs 18.25 lakh for allegedly violating green norms
Hyderabad: Violation of pollution control norms has costed eight pharmaceutical units each, including Hetero Labs, Aurobindo Pharma, and Mylan Laboratories that have been told to pay environmental compensation of Rs 18.25 lakh by the Telangana State Pollution Control Board (TSPCB).
The pharma firms in the soup are Hetero Labs, Shilpa Medicare, Aurobindo Pharma(two units), APL Health Care, Mylan Laboratory, Evertogen Life Sciences, Shri Kartikeya Pharma and Amneal Oncology.
As per a recent media report in The New Indian Express, TSPCB has further imposed a penalty on one pharma unit at the TSIIC SEZ in Polepally of Mahbubnagar district. However, TSPCB has allegedly acted in a biased manner as it considered only 365 days of violation whereas the original number of days is three times than that.
TSPCB has reportedly submitted the details of the environmental compensation to the National Green Tribunal (NGT), based on the 'polluter pays' principle.
The NGT formed a joint committee in 2019 combining the officials of the State and the Central Government. The committee submitted its findings based on the complaints of pollution by pharmaceutical companies located inside the Polepally SEZ.
Recently, TSPCB issued individual notices to the pharmaceutical companies mentioning the number of days of the violation. However, the number of days in most cases was reportedly more than 1,100 days and in fact in some cases more than 1,300 days.
However, TSPCB had allegedly considered three units of a pharmaceutical company together while imposing compensation. In the case of another company, it has considered two units as separate.
Sravan Kumar, an advocate and also a petitioner of the case, recently pointed out this aspect of alleged bias to the NGT. He claimed that TSPCB has considered only 365 days of violation whereas the actual numbers are far greater.
Based on this, the NGT, presently hearing the petition in the matter has given direction to TSPCB for reviewing the amount of compensation on Friday. The NGT has asked TSPCB to submit a final report regarding the same after conducting a thorough revise.
Also Read: PIL filed before NGT over violation of bio-medical waste disposal in Bengal
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.